Kamada Competitors

Mersana Therapeutics (NASDAQ:MRSN) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Mersana Therapeutics and Kamada, as reported by MarketBeat.

Mersana Therapeutics presently has a consensus target price of $26.1667, indicating a potential upside of 65.51%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Kamada's stronger consensus rating and higher probable upside, analysts clearly believe Kamada is more favorable than Mersana Therapeutics.

Profitability

This table compares Mersana Therapeutics and Kamada's net margins, return on equity and return on assets.

Risk and Volatility

Mersana Therapeutics has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

14.3% of Kamada shares are held by institutional investors. 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mersana Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Mersana Therapeutics on 10 of the 14 factors compared between the two stocks.

Constellation Pharmaceuticals (NASDAQ:CNST) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Constellation Pharmaceuticals and Kamada, as reported by MarketBeat.

Constellation Pharmaceuticals presently has a consensus target price of $45.2857, indicating a potential upside of 101.27%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Constellation Pharmaceuticals' higher probable upside, analysts clearly believe Constellation Pharmaceuticals is more favorable than Kamada.

Profitability

This table compares Constellation Pharmaceuticals and Kamada's net margins, return on equity and return on assets.

Risk and Volatility

Constellation Pharmaceuticals has a beta of 2.8, indicating that its share price is 180% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

14.3% of Kamada shares are held by institutional investors. 10.6% of Constellation Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Constellation Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Zogenix (NASDAQ:ZGNX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Zogenix and Kamada, as reported by MarketBeat.

Zogenix presently has a consensus target price of $58.25, indicating a potential upside of 202.28%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Zogenix's higher probable upside, analysts clearly believe Zogenix is more favorable than Kamada.

Profitability

This table compares Zogenix and Kamada's net margins, return on equity and return on assets.

Risk and Volatility

Zogenix has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Insider and Institutional Ownership

96.6% of Zogenix shares are held by institutional investors. Comparatively, 14.3% of Kamada shares are held by institutional investors. 3.5% of Zogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Zogenix and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Zogenix on 8 of the 14 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Trillium Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.5% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Trillium Therapeutics and Kamada, as reported by MarketBeat.com.

Trillium Therapeutics presently has a consensus target price of $22.00, indicating a potential upside of 111.13%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Kamada.

Volatility and Risk

Trillium Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares Trillium Therapeutics and Kamada's net margins, return on equity and return on assets.

Summary

Kamada beats Trillium Therapeutics on 8 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares G1 Therapeutics and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for G1 Therapeutics and Kamada, as reported by MarketBeat.com.

G1 Therapeutics presently has a consensus target price of $49.1667, indicating a potential upside of 92.28%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given G1 Therapeutics' higher probable upside, equities analysts plainly believe G1 Therapeutics is more favorable than Kamada.

Volatility and Risk

G1 Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares G1 Therapeutics and Kamada's net margins, return on equity and return on assets.

Summary

Kamada beats G1 Therapeutics on 7 of the 12 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Syndax Pharmaceuticals and Kamada's top-line revenue, earnings per share and valuation.

Kamada has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.3% of Kamada shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Syndax Pharmaceuticals and Kamada, as reported by MarketBeat.com.

Syndax Pharmaceuticals presently has a consensus target price of $28.5455, indicating a potential upside of 28.82%. Kamada has a consensus target price of $11.00, indicating a potential upside of 79.15%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Syndax Pharmaceuticals.

Volatility and Risk

Syndax Pharmaceuticals has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Kamada has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and Kamada's net margins, return on equity and return on assets.

Summary

Kamada beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.